ADRs In The News: Redux, Rezulin And Lupron Receiving Unwanted Attention
Executive Summary
The handling of adverse event reports that led to the withdrawal of Wyeth-Ayerst's Redux (fenfluramine) is expected to be the subject of a "60 Minutes II" segment scheduled to air Feb. 3.